US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Avalyn Pharma

38.37

+1.243.34%

Volume:159.50K

Turnover:6.13M

Market Cap:1.70B

PE:-16.47

High:39.68

Open:37.13

Low:37.06

Close:37.13

52wk High:40.17

52wk Low:24.15

Shares:44.33M

Float Shares:16.67M

Volume Ratio:0.93

T/O Rate:0.96%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.3300

EPS(LYR):-87.7434

ROE:-68.34%

ROA:-41.74%

PB:4.27

PE(LYR):-0.44

Loading ...

Overview Company News Filings

Analyst Reiterates Buy on Avalyn, Citing Inhaled IPF/PPF Pipeline and Multiple Revenue Streams to Support $52 Price Target

Avalyn Pharma initiated with a Buy at Jefferies

U.S. RESEARCH ROUNDUP- Analog Devices, Crowdstrike, Deere & Co

Avalyn Pharma Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $80

THOMSON REUTERS

BRIEF-Avalyn Announces Additional Long-Term Data On Ap01, Inhaled Pirfenidone, For The Treatment Of Pulmonary Fibrosis

Avalyn to present 4-year ATLAS data for inhaled pirfenidone AP01 at EULAR 2026

Avalyn Announces Additional Long-Term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to Be Presented at the European Alliance of Associations for Rheumatology 2026

THOMSON REUTERS

Novo Holdings acquires 555,555 Avalyn Pharma common shares for $10 million

Avalyn presents AP01 eFlow nebulizer usability study data at ATS 2026

Major Insider Moves Signal Growing Confidence in Avalyn Pharma

Avalyn Pharma Closes Initial Public Offering

MT Newswires Live

Top Midday Gainers

MT Newswires Live

Avalyn Pharma indicated to open at $25.25, IPO priced at $18.00

Stock Track | Avalyn Pharma Soars 44.44% in Intraday Trading on Nasdaq IPO Debut

Avalyn Pharma Sets IPO at $18 Per Share to Raise $300 Million, Listing on Nasdaq Tonight

Avalyn Pharma 16.67M share IPO priced at $18.00

BRIEF-Avalyn Announces Pricing Of Upsized Initial Public Offering

Avalyn Announces Pricing of Upsized Initial Public Offering

THOMSON REUTERS

Avalyn Pharma Inc - Prices Upsized IPO of 16,666,667 Shares at $18.00 per Share

THOMSON REUTERS

Avalyn Pharma Sets IPO at 16.7 Million Shares Priced at $16-$18 Each

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/AVLN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","market":"US","secType":"STK","nameCN":"Avalyn Pharma","latestPrice":38.37,"timestamp":1787342400000,"preClose":37.13,"halted":0,"volume":159499,"delay":0,"changeRate":0.03339617559924575,"floatShares":16666700,"shares":44333095,"eps":-2.33,"marketStatus":"Pre-Mkt","change":1.24,"latestTime":"08-24 04:44:03 EDT","open":37.13,"high":39.68,"low":37.06,"amount":6129958.07742,"amplitude":0.070563,"askPrice":38.27,"askSize":1,"bidPrice":30,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-2.33,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"listingDate":1777521600000,"exchange":"NASDAQ","adjPreClose":38.37,"postHourTrading":{"tag":"盘后","latestPrice":38.37,"preClose":38.37,"latestTime":"19:30 EDT","volume":1584,"amount":60778.08,"timestamp":1787355006472,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9294456042359872,"impliedVol":0.6262,"impliedVolPercentile":1},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","floatShares":16666700,"roa":"-41.74%","roe":"-68.34%","lyrEps":-87.743381,"volumeRatio":0.9294456042359872,"shares":44333095,"dividePrice":0,"high":39.68,"amplitude":0.070563,"preClose":37.13,"low":37.06,"week52Low":24.15,"pbRate":"4.27","week52High":40.17,"institutionHeld":0,"latestPrice":38.37,"committee":0.5,"eps":-2.33,"divideRate":0,"volume":159499,"delay":0,"ttmEps":-2.33,"open":37.13,"prevYearClose":18,"prevWeekClose":38.37,"prevMonthClose":28.79,"prevQuarterClose":32.92,"fiveDayClose":39.25,"twentyDayClose":27.95,"sixtyDayClose":26.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVLN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"AVLN","fiscalQuarterEnding":"2026/06","expectedEps":-1.03,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"pre","actualEps":-0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVLN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1781755200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVLN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVLN","date":"2026-08-21","current":-16.467811,"percent":0.103896,"low":-16.842577,"twenty":-15.087944,"median":-13.934398,"eighty":-13.227101,"high":-8.833116,"avg":-14.127835,"sd":1.262939,"marketCap":1646087817},"quantilePoints":[{"date":"2026-05-01","current":-14.471589,"twenty":-13.343894,"median":-11.652352,"eighty":-9.960811,"marketCap":1233037266},{"date":"2026-05-08","current":-13.215324,"twenty":-14.430368,"median":-13.598092,"eighty":-13.264397,"marketCap":1125998425},{"date":"2026-05-15","current":-15.026112,"twenty":-14.666899,"median":-14.368536,"eighty":-13.42143,"marketCap":1280284879},{"date":"2026-05-22","current":-13.941602,"twenty":-14.643344,"median":-13.941602,"eighty":-13.42143,"marketCap":1187880255},{"date":"2026-05-29","current":-13.931787,"twenty":-14.643344,"median":-13.931787,"eighty":-13.215324,"marketCap":1187044014},{"date":"2026-06-05","current":-13.244767,"twenty":-14.510847,"median":-13.774754,"eighty":-13.102456,"marketCap":1128507148},{"date":"2026-06-12","current":-13.774754,"twenty":-14.471589,"median":-13.774754,"eighty":-13.161343,"marketCap":1173664159},{"date":"2026-06-18","current":-14.383258,"twenty":-14.479441,"median":-13.794383,"eighty":-13.204528,"marketCap":1225511097},{"date":"2026-06-26","current":-13.585419,"twenty":-14.649233,"median":-13.936694,"eighty":-13.238878,"marketCap":1284773093},{"date":"2026-07-02","current":-14.143275,"twenty":-14.655122,"median":-14.03484,"eighty":-13.265378,"marketCap":1337529476},{"date":"2026-07-10","current":-13.557292,"twenty":-14.643344,"median":-13.937009,"eighty":-13.265378,"marketCap":1282113107},{"date":"2026-07-17","current":-12.038425,"twenty":-14.576758,"median":-13.784568,"eighty":-13.15846,"marketCap":1138473879},{"date":"2026-07-24","current":-13.937009,"twenty":-14.519455,"median":-13.774754,"eighty":-13.193732,"marketCap":1318022914},{"date":"2026-07-31","current":-13.740119,"twenty":-14.495144,"median":-13.755125,"eighty":-13.157019,"marketCap":1299403014},{"date":"2026-08-07","current":-15.329303,"twenty":-14.523759,"median":-13.762486,"eighty":-13.165961,"marketCap":1449692206},{"date":"2026-08-14","current":-15.696852,"twenty":-14.725787,"median":-13.774754,"eighty":-13.189862,"marketCap":1621704615},{"date":"2026-08-21","current":-15.932863,"twenty":-15.087944,"median":-13.934398,"eighty":-13.227101,"marketCap":1646087817}],"updateTime":1787535224740},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVLN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638537028","title":"Analyst Reiterates Buy on Avalyn, Citing Inhaled IPF/PPF Pipeline and Multiple Revenue Streams to Support $52 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2638537028","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638537028?lang=en_us&edition=fundamental","pubTime":"2026-05-25 19:26","pubTimestamp":1779708363,"startTime":"0","endTime":"0","summary":"Roger Song, an analyst from Jefferies, has initiated a new Buy rating on Avalyn Pharma Inc (AVLN). Roger Song has given his Buy rating due to a com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-avalyn-citing-inhaled-ipf-ppf-pipeline-and-multiple-revenue-streams-to-support-52-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-avalyn-citing-inhaled-ipf-ppf-pipeline-and-multiple-revenue-streams-to-support-52-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638537948","title":"Avalyn Pharma initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2638537948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638537948?lang=en_us&edition=fundamental","pubTime":"2026-05-25 19:05","pubTimestamp":1779707104,"startTime":"0","endTime":"0","summary":"Jefferies initiated coverage of Avalyn Pharma (AVLN) with a Buy rating and $52 price target The firm says the company is “solving right problem in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638366536","title":"U.S. RESEARCH ROUNDUP- Analog Devices, Crowdstrike, Deere &  Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2638366536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638366536?lang=en_us&edition=fundamental","pubTime":"2026-05-25 16:32","pubTimestamp":1779697943,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Analog Devices, Crowdstrike, Deere &  CoMay 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including An","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nL4N4220EH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADI","HEI","CRWD","PS","FTNT","SG9999004303.SGD","LU0477156953.USD","BK4560","DOGD","LU1623119135.USD","LU2023250504.SGD","BK4551","DE","DDOG","LU1923623000.USD","LU1989764664.SGD","IE00B1BXHZ80.USD","BK4515","LU1917777945.USD","LU2491049909.HKD","PALU","LU0868494708.USD","LU2211815571.USD","BJ","LU2487616109.SGD","LU0724618433.USD","LU1989763690.USD","LU2125909247.SGD","LU2286300806.USD","PANW","IE0008368304.USD","LU2298322129.HKD","LU1670711123.USD","LU0124384867.USD","LU2023250843.SGD","LU0314104364.USD","SG9999011175.SGD","LU2394011477.USD","PALD","IE00BZ199S13.USD","LU0957808578.USD","CRWL","LPG","LU0170899867.USD","BK4152","LU2125909916.SGD","IE00B19Z8X17.USD","PANG","AVLN","LU0511384066.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638582653","title":"Avalyn Pharma Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $80","url":"https://stock-news.laohu8.com/highlight/detail?id=2638582653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638582653?lang=en_us&edition=fundamental","pubTime":"2026-05-25 12:21","pubTimestamp":1779682872,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nFWN41Z0Y2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637363563","title":"BRIEF-Avalyn Announces Additional Long-Term Data On Ap01, Inhaled Pirfenidone, For The Treatment Of Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363563","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637363563?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:38","pubTimestamp":1779367120,"startTime":"0","endTime":"0","summary":"BRIEF-Avalyn Announces Additional Long-Term Data On Ap01, Inhaled Pirfenidone, For The Treatment Of Pulmonary FibrosisMay 21 (Reuters) - Avalyn Pharma Inc AVLN.O:AVALYN ANNOUNCES ADDITIONAL LONG-TERM ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUAKXWKT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333281","title":"Avalyn to present 4-year ATLAS data for inhaled pirfenidone AP01 at EULAR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333281","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333281?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:01","pubTimestamp":1779364915,"startTime":"0","endTime":"0","summary":"Avalyn Pharma flagged additional long-term data from the ATLAS open-label extension study of AP01, an inhaled version of pirfenidone, with results scheduled for presentation at EULAR 2026 on June 6 in London.The update is set to focus on long-term tolerability in patients with progressive pulmonary fibrosis treated for up to four years.Avalyn also pointed to prior studies suggesting AP01 could help preserve lung function while improving tolerability versus historical oral pirfenidone, a positioning that supports its ongoing Phase 2b MIST trial in progressive pulmonary fibrosis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL9kwy0p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","AVLN","BK4007","SG9999014039.USD","IE00BN0W2V16.EUR","BK4588","IE00BN0W2W23.USD","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","BK4112","BK4585","LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333431","title":"Avalyn Announces Additional Long-Term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to Be Presented at the European Alliance of Associations for Rheumatology 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333431?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUAKXWKT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633299269","title":"Novo Holdings acquires 555,555 Avalyn Pharma common shares for $10 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633299269","media":"Reuters","labels":["insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633299269?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:16","pubTimestamp":1778012202,"startTime":"0","endTime":"0","summary":"Novo Holdings, a 10% owner, lifted its stake in Avalyn Pharma to 3,883,289 voting common shares.Holding increased through conversion of 3,327,734 shares into voting common stock.Novo Holdings also bought 555,555 voting common shares at USD 18 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalyn Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL7C7q1x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Novo Holdings acquires 555,555 Avalyn Pharma common shares for $10 million","news_tag":"insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459925","title":"Avalyn presents AP01 eFlow nebulizer usability study data at ATS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459925","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459925?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:03","pubTimestamp":1778011381,"startTime":"0","endTime":"0","summary":"Avalyn Pharma flagged new patient-centered research on AP01 delivery and supportive care experiences, with results scheduled for presentation at American Thoracic Society 2026 International Conference in Orlando on May 18, 2026.A usability study of eFlow nebulizer system for inhaled pirfenidone AP01 found patient, care partner, clinician feedback helped refine instructions intended to improve real-world use.Separate research on idiopathic pulmonary fibrosis supportive care highlighted patient demand for faster, clearer communication, stronger care partner involvement, better access to specialist expertise.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDLbFxw9M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","AVLN","SG9999014039.USD","IE00BN0W2V16.EUR","BK4588","IE00BN0W2W23.USD","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","BK4112","BK4585","LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632327621","title":"Major Insider Moves Signal Growing Confidence in Avalyn Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2632327621","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632327621?lang=en_us&edition=fundamental","pubTime":"2026-05-02 10:02","pubTimestamp":1777687366,"startTime":"0","endTime":"0","summary":"New insider activity at Avalyn Pharma Inc ( ($AVLN) ) has taken place on May 1, 2026. Avalyn Pharma Inc. has seen notable insider confidence, with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-insider-moves-signal-growing-confidence-in-avalyn-pharma-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-insider-moves-signal-growing-confidence-in-avalyn-pharma-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632475756","title":"Avalyn Pharma Closes Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2632475756","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632475756?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:16","pubTimestamp":1777666562,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (AVLN) said late Friday it has closed its initial public offering of about 19.2 million shares at $18 a share, raising $345 million.The clinical-stage biopharmaceutical company said the closing includes the full exercise of an overallotment option.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPOS","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632650002","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2632650002","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632650002?lang=en_us&edition=fundamental","pubTime":"2026-05-01 02:29","pubTimestamp":1777573776,"startTime":"0","endTime":"0","summary":"Avalyn Pharma , a clinical-stage drugmaker, said late Wednesday it has priced its upsized initial public offering of about 16.7 million shares at $18.00 apiece, targeting gross proceeds of about $300 million.Shares soared in their trading debut on Nasdaq, up over 50% at about $27.44 in afternoon trading, with intraday trading volume of over 3.65 million.Everspin Technologies  reported Thursday an agreement with a US prime contractor to provide Toggle MRAM process technology and engineering services for United States Defense Industrial Base customers. The agreement is valued at $40.0 million and will run over two-and-a-half years.Shares surged 37% as intraday trading volume soared to over 12.6 million from a daily average of about 533,000.Viavi Solutions  jumped 15% after its fiscal Q3 results and fiscal Q4 guidance exceeded market expectations.More than 15.1 million shares traded intraday, compared with a daily average of about 5.87 million.Price: 27.00, Change: +9.00, Percent Change: ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4141","LU0205194284.USD","LU0566484027.USD","LU2065171402.SGD","LU2065170008.USD","LU0240878834.USD","MRAM","LU2065169927.USD","LU0240877869.USD","AVLN","LU1559883803.SGD","LU2065171311.SGD","BK4020","LU0205193047.USD","VIAV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632501116","title":"Avalyn Pharma indicated to open at $25.25, IPO priced at $18.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2632501116","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632501116?lang=en_us&edition=fundamental","pubTime":"2026-05-01 02:10","pubTimestamp":1777572602,"startTime":"0","endTime":"0","summary":"12:03 EDT Avalyn Pharma (AVLN) indicated to open at $25.25, IPO priced at $18.00 Published first on TheFly – the ultimate source for real-time, mar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-indicated-to-open-at-25-25-ipo-priced-at-18-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-indicated-to-open-at-25-25-ipo-priced-at-18-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVLN","IPOS","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133662273","title":"Stock Track | Avalyn Pharma Soars 44.44% in Intraday Trading on Nasdaq IPO Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1133662273","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133662273?lang=en_us&edition=fundamental","pubTime":"2026-05-01 01:26","pubTimestamp":1777570002,"startTime":"0","endTime":"0","summary":"Avalyn Pharma's stock soared 44.44% in intraday trading on Thursday as the clinical-stage biopharmaceutical company made its trading debut on the Nasdaq Global Select Market.The company's upsized...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115675476","title":"Avalyn Pharma Sets IPO at $18 Per Share to Raise $300 Million, Listing on Nasdaq Tonight","url":"https://stock-news.laohu8.com/highlight/detail?id=1115675476","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115675476?lang=en_us&edition=fundamental","pubTime":"2026-04-30 15:01","pubTimestamp":1777532510,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (AVLN.US), a clinical-stage biotechnology company focused on developing inhaled therapeutics for rare respiratory diseases, has priced its initial public offering at $18 per share. The...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONEQ","JEPQ","TQQY","QQQE","QDTE","QQQY","QQQA","SQQQ","AVLN","GPIQ","NVIW.SI","PSQ","MNQmain","IYW","QQQM","QID","QYLG","QQQ","BK1147","QLD","BK4007","TQQQ","FTEC","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631083415","title":"Avalyn Pharma 16.67M share IPO priced at $18.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2631083415","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631083415?lang=en_us&edition=fundamental","pubTime":"2026-04-30 11:35","pubTimestamp":1777520126,"startTime":"0","endTime":"0","summary":"The deal priced at the top end of its $16.00-$18.00 target range. Morgan Stanley, Jefferies, Evercore ISI and Guggenheim are acting as joint book r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-16-67m-share-ipo-priced-at-18-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-16-67m-share-ipo-priced-at-18-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1244550221.USD","BK4534","LU1244550577.SGD","LU0528227936.USD","LU1162221912.USD","LU1791710400.SGD","LU2347655156.SGD","LU1363072403.SGD","IE00BKVL7J92.USD","LU0557290698.USD","LU2133065610.SGD","LU0912757837.SGD","LU2089283258.USD","LU0158827781.USD","BK4581","BK4516","LU0795875169.SGD","IE00BZ1G4Q59.USD","IPOS","LU1989772840.SGD","LU0006306889.USD","LU0267386448.USD","LU1732800096.USD","LU1244550494.USD","LU0795875086.SGD","LU1074936037.SGD","LU2271345857.HKD","LU0158827948.USD","LU2028103732.USD","BK4585","SPCX","LU0225283273.USD","LU1720051108.HKD","LU2023251221.USD","BK4504","AVLN","BK4127","LU0098860793.USD","LU0314104364.USD","LU1732799900.SGD","LU0106261372.USD","LU0882574139.USD","LU1720051017.SGD","LU2111349929.HKD","LU0320765646.SGD","LU1791710582.SGD","LU2089284900.SGD","LU2357305700.SGD","LU1668664300.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631657927","title":"BRIEF-Avalyn Announces Pricing Of Upsized Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2631657927","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631657927?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:05","pubTimestamp":1777511117,"startTime":"0","endTime":"0","summary":"BRIEF-Avalyn Announces Pricing Of Upsized Initial Public OfferingApril 29 (Reuters) - Avalyn Pharma Inc AVLN.O:AVALYN ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERINGAVALYN PHARMA INC - PRICES UPS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA49XTQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631657919","title":"Avalyn Announces Pricing of Upsized Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2631657919","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631657919?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:00","pubTimestamp":1777510853,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA49XTQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631579417","title":"Avalyn Pharma Inc - Prices Upsized IPO of 16,666,667 Shares at $18.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2631579417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631579417?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:00","pubTimestamp":1777510853,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA49XTQ6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631545444","title":"Avalyn Pharma Sets IPO at 16.7 Million Shares Priced at $16-$18 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2631545444","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631545444?lang=en_us&edition=fundamental","pubTime":"2026-04-29 23:01","pubTimestamp":1777474860,"startTime":"0","endTime":"0","summary":"Avalyn Pharma on Wednesday plans to sell nearly 16.7 million shares at between $16 and $18 apiece in its initial public offering.At the $17 midpoint of that range, the Boston clinical-stage biopharmaceutical company said it expects net proceeds of about $258.7 million, or roughly $298.2 million if the underwriters exercise an option to buy an additional 2.5 million shares.Avalyn, which is developing inhaled therapies to treat rare respiratory diseases with significant unmet needs, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operations into 2029.Avalyn said it would have about 44.3 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a market capitalization topping $750 million at the $17-a-share pricing midpoint.The company said it has applied to list its shares on the Nasdaq Global Market under the symbol AVLN.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","SPCX","AVLN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":45,"code":"91000000","status":"200"}]}}